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Background: While ethicists have for many years called for human subject trial participants and, in some cases,
local community members to benefit from participation in pharmaceutical and other intervention-based therapies,
little is known about how these discussions are impacting the practice of research ethics boards (REBs) that grant
ethical approval to many of these studies.
Methods: Telephone interviews were conducted with 23 REB members from across Canada, a major funder country
for human subject research internationally. All interviews were digitally recorded and transcribed verbatim. After
coding, the data was analyzed to identify central themes and topics. Themes were identified, application of the themes
was confirmed, and these themes were then used to populate the findings of this manuscript.
Results: Our analysis of the interviews identified two primary themes when considering what benefits are owed to
research participants and their communities. 1) Most study participants felt that given that these studies are led by
persons in the role of researcher rather than health care provider, they had a limited obligation to provide benefits to
study participants. 2) These REB members were all working in Canada, a high income country where most residents
enjoy high levels of access to health care. As a result of this context, the study participants tended to focus on ethical
concerns including obtaining informed consent and avoiding undue inducement to participate in research rather than
ensuring that study participants directly benefit from successful trials.
Conclusions: Research on REB members’ attitudes toward what benefits are owed to study participants and
community members is needed in other countries in order to determine how context affects these attitudes.
Keywords: Post-trial access, Fair benefits, Reasonable availabilityBackground
Before a medical intervention can be judged effective it
must generally be evaluated through clinical trials, which
hinge on the participation of human subjects. While
there are strict requirements relating to the treatment of
human participants during clinical trials, there are often
few requirements around a researcher’s obligation to
participants once the trial ends [1]. In the case of phar-
maceuticals and other intervention-based therapies, this
could mean access to a potentially beneficial treatment
would end when the trial ends.
Benefits accruing from trial participation, including
post-trial access to the pharmaceutical, therapy, or inter-
vention under investigation after the study period, can* Correspondence: jeremycsnyder@sfu.ca
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While post-trial access may not be such a pressing issue
for participants in high-income countries with access to
publically funded drug plans, participants in other parts
of the world may lose access to beneficial treatments at
the end of a trial [4]. A similar and related concern ex-
ists around benefits for community members, particu-
larly in low-income communities and countries.
Community members may shoulder some of the bur-
dens of research trials, such as supporting friends and
family or being affected by new infrastructure, even if
they do not participate directly in the research or gain
any direct benefits from the trial [5, 6].
Research Ethics Boards (REBs) are a key group in
evaluating the ethical requirements of human subject re-
search, but little is known about their views towards
benefits for participants and other community members.s distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ics board members was by Pace et al. (2006) who used
telephone and self-administered surveys to study atti-
tudes towards post-trial access. Pace reported contextual
difference between REB members’ views, with chairs
from Europe and South America more likely than those
in the United States, Australia, and China to endorse
providing drugs from the trial free of charge to partici-
pants [7]. More recently, Dainesi and Golbaum (2012)
used an e-survey to investigate the views of major stake-
holders in Brazil around post-trial access, including clin-
ical investigators and ethics committee members. The
majority of ethics committee members questioned be-
lieved that all participants should have access to the
studied intervention post-trial [8].
This paper builds on this work by examining the atti-
tudes of REB members regarding what benefits are owed
to research participants and their communities and the
ethical rationale for requiring these benefits. The 23 REB
members interviewed in this study are all based in
Canada, a high-income country that is and will continue
to be a funder country for clinical trials in low-income
countries and therefore serve as an initial gatekeeper via
research ethics review of studies that would take place
amongst vulnerable populations. These REBs are gov-
erned by the revised Tri-Council Policy Statement
(TCPS2) on Ethical Conduct for Research Involving
Humans, which states that prior to conducting research
with human participants, researchers should “outline the
scope and nature of potential benefits that may accrue
to participants during and after he research” and “ensure
that the proposed distribution of benefits is fair, without
imposing undue burdens on the researcher that would
make it too difficult or costly to complete research” [9].
Thus, while TCPS2 notes that fairness in the distribution
of benefits is a concern for researchers, it does not pro-
vide clear guidance on what benefits from clinical trials
are necessary, making better understanding of the atti-
tudes of Canadian REB members on this issue of great
value.
Methods
The purpose of this qualitative study was to explore atti-
tudes of REB members regarding benefits owed to re-
search participants and communities. To address this,
phone interviews with REB members were conducted in
the spring of 2014.
Ethics, consent, and permissions
Participant recruitment started after approval for this
study was received from the Research Ethics Board at
Simon Fraser University. Using only publicly accessible
information on university websites, REB members were
contacted via email. The email contained informationabout the study, contact details of the researchers, and
offered a $50 honorarium. Consent to participate was re-
ceived from all participants.
Recruitment
The researchers identified all Canadian universities with
associated medical schools, and used public information
on the universities’ websites to identify REB members
where this information was publicly available. These
membership lists included academic and lay members
who constituted the REB. All participants were current
or recent REB members. Where information was avail-
able, the researchers contacted members of REBs that
reviewed research involving biomedical, health sciences,
and health social sciences. Snowball sampling was not
used as those universities that published REB member-
ship lists published complete lists and REB members
were not expected to have knowledge of REB member-
ship at other universities.
REB members were recruited from Alberta (n = 1),
British Columbia (n = 7), Manitoba (n = 1), Ontario (n =
11), Saskatchewan (n = 4). They represented a range of
academic disciplines, including medicine (n = 6), ethics
(n = 2), kinesiology (n = 2), nursing (n = 2), pharmacology
(n = 2), psychiatry (n = 2), engineering (n = 1), environ-
mental studies (n = 1), geography (n = 1), health sciences
(n = 1), linguistics (n = 1), plant sciences (n = 1), and so-
cial sciences (n = 1). No lay REB members contacted
agreed to participate in this study.
Data collection
In total, 23 phone interviews were completed, each last-
ing approximately 45 minutes and conducted by one re-
searcher. Participants had varying experiences with the
subject matter being discussed in the interviews, and
had varying research and academic backgrounds, result-
ing in a wide variety of views on the subject matter.
As the researchers were trying to capture a broad array
of views on the subject matter, certain terms used in the
interviews were kept intentionally general. “Research
participants” were defined as those directly participating
in research, while “community members” were defined
as those not directly participating in research, but who
may be impacted by the research in some way. “Benefits”
could be any positive impact of research, be it tangible
or intangible. Tables 1, 2, 3, 4 and 5 contain sample
questions asked of the research participants, each of
which was followed by more specific probes.
Analysis
All interviews were digitally recorded and transcribed
verbatim. The transcripts were uploaded into NVivo
qualitative data management software and reviewed by
the first and second authors. A coding scheme was
Table 3 Why are these benefits for participants morally
required?
Response Count
Transparency 5
Offering anything would be coercive 3
Cost prevents offering benefits 2
Not the role of the researcher 1
Fairness and reciprocity 14
Table. 1 Are there requirements around benefits for research
participants?
Response Count
No 12
No direct benefit, but a societal benefit 7
Proportional benefit 3
Unsure 1
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the first two co-authors conducting an independent re-
view of the transcripts. The first two co-authors met to
compare observations on these transcripts and reached
consensus on a set of dominant issues emerging from
the transcripts that would be used for developing the
coding scheme. The transcripts were coded by the first
author and confirmed by the second author in order to
support the credibility of the application of the coding
scheme. After coding, the coded data was analyzed by
the first two co-authors to identify central themes and
topics. Themes were identified, application of the themes
was confirmed by the first and second authors who also
confirmed representativeness of the themes across tran-
scripts, and these themes were then used to populate the
findings of this manuscript.
Results
Benefits for participants
Respondents indicated that they were familiar with the
challenges and issues around providing benefits for par-
ticipants, and most explained that they had considered
these issues through their role as REB members. Most
respondents indicated that Canadian law does not re-
quire benefits for research participants (see Table 1), al-
though there was some confusion around “legal”
requirements following from TCPS2 versus common
practices. Several respondents specified that their role as
an REB member was to ensure protection from harm,
but that this did not involve ensuring benefits for partic-
ipants. As one respondent explained, “The ultimate goal
of an ethics committee is to maximize the safety of a per-
son who volunteers to participate in a study. There is ab-
solutely no guarantee of benefit and that’s supposed to be
stated on virtually all consent forms.” Another commonTable 2 What do you think is morally required, in terms of
benefits for participants?
Response Count
Knowledge 13
Not worse off, compensated for expenses or time 11
Continued access to interventions 6
Whatever benefits were specified in the consent form 5
No benefits 1concern was that while no benefits are required, it is
crucially important that researchers clearly communicate
this to participants during the consent process.
There was some confusion around what was explicitly
required by the REBs and what was common practice.
As one respondent noted, “I think the requirements are
a little fuzzy… Rather than being direct in stating what
is expected or what is required. I think that speaks to the
different funding arrangements and the different policy
frameworks…” Over the course of the interviews, several
participants singled out funders as having some control
over benefits for participants, or dictating benefits in
some way.
A key recurring theme throughout almost all of the in-
terviews was a concern around undue inducement to
participate in a study. One REB member stated, “…it’s
pretty unclear as to what …is defined as an appropriate
amount of compensation for folks, when does something
become more coercive than others.” Approximately one
third of respondents took a broad view of benefits for
participants and indicated that while no direct benefits
were required by REBs, all research had to have some
expected benefit for society as a whole such as contrib-
uting to new advances in technology or to societal
knowledge in general. One respondent explained, “you
can’t just go around sticking pins into people and draw-
ing their blood unless there’s at least a legitimate intent
to … provide a cure for something or to understand a
disease.”
A few respondents specified that the potential benefits
to participants be proportional to the risk they experi-
enced through their participation in the research, with
some respondents indicating that this is often a difficult
balance to strike: “My understanding is that we’re always
looking at proportionality, …that there is some kind ofTable 4 Are there requirements around benefits for community
members?
Response Count
Nothing 9
Generalizable knowledge 8
Study results 2
Unsure 1
Table 5 What do you think is morally required, in terms of
benefits for participants?
Response Count
Access to information 18
Access to the intervention 3
No benefits 2
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ther directly or indirectly.”
When respondents were asked what they themselves
thought was morally required in terms of benefits to
participants, regardless of existing legal requirements or
norms, the answers were markedly different from those
around legal requirements. The two most common re-
sponses had to do with compensating participants for
their time and expenses and for increasing knowledge
(see Table 2). Compensation for participants’ expenses
included reimbursing them for transportation costs, as
well as providing financial compensation for their time.
Several participants made a clear distinction between
“benefits” for participants and “compensation” for time
and expenses: “definitely the out of pocket expenses, I be-
lieve is a bare minimum.” Others considered compensa-
tion to be an impermissible benefit.
Again, undue inducement was mentioned several
times as a key consideration when compensating partici-
pants. One researcher described this dilemma in the
context of their own research: “…what I offer to do in
my own research is pay any sort of transit or transporta-
tion costs and then I have a small honorarium that sort
of represents the hour that they’ve given for an interview
… But I think that’s very different than paying someone
$500 to do an interview.”
Increasing knowledge was the second common theme
around morally required benefits for participants. For
some, this meant a commitment to research that will
further our collective understanding of a disease or ther-
apy, while others included self-knowledge and under-
standing gained through the research process. Multiple
respondents described access to study results as the
“minimum” for ethical research. For one respondent, in-
creasing knowledge comprised several areas: “…I think
they need to learn something from the process… I think
they need to learn their own medical results and… I
think that they have a right to know what the trial
accomplished.”
Several respondents focused not on the specific
benefits that participants should receive, but on the
transparency of the consent process. These respon-
dents felt that participants are entitled to whatever
was specified in the consent form, and stressed that
true consent from participants was more important
than the precise benefits offered. Generally, theseresponses emphasized the need for informed consent
and the ability of participants to choose to participate
without undue inducement or coercion. One re-
searcher described this view as being “a pretty typical
one,” while another explained, “… the requirement is
really to make it clear what benefits are including, in-
cluding in many cases none.”
A final recurring theme was continued access to an
intervention or therapy as a moral requirement of re-
search. Some felt that this should be a requirement
for all research, while others specified that access to
the intervention being studied should only be ex-
tended past the end of the study if no other alterna-
tives are available: “…if it’s truly a unique medication
for a unique problem then there should be some way
in which they can get privileged access.” Several re-
spondents indicated that while they supported contin-
ued access to an intervention, they had reservations
about the practical implementation of such a require-
ment: “…if you’re going to say … these benefits have
to keep going after the research I think there’s going to
be a lot of research …that will stop because of the
money issue.”
When asked why they believe certain benefits are mor-
ally required, some participants provided rationales for
not providing benefits, such as: it is not the role of re-
searchers to offer benefits; cost prevents researchers
from offering benefits; offering anything would be coer-
cive; and transparency, including honouring consent
forms (see Table 3). One respondent explained that re-
searchers are “not out there to continue to treat, they’re
actually there to do the research and provide the know-
ledge,” and that “it’s up to the… country and the prov-
inces to decide what they want to actually provide.”
Another respondent explained that, “funding is difficult
to come by” and requiring certain benefits would limit
unfunded research conducted by students and profes-
sors. Several respondents believed that providing any
benefits at all could be coercive and unethical. These re-
spondents stressed the “voluntary” and “non-obligatory”
aspects of research participation. Again, several respon-
dents stressed that as long as participants freely agree to
participate in research, no additional benefits are morally
required.
The rationales for providing benefits focused almost
exclusively on fairness and reciprocity. Many respon-
dents cited proportionality as a consideration within
fairness, with one respondent explaining, “… it’s defin-
itely ethically desirable that participants receive some
benefit from participating in a trial that is related to
the risks that they’re assuming and the time that
they’re putting in as research subjects.” Other respon-
dents emphasized knowledge exchange and a “quid
pro quo” approach to research.
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The interview participants generally struggled with spe-
cifying benefits for community members, with several
participants explaining that they had never considered
benefits for community members in their role as an REB
member. The most common responses were that com-
munity members were either owed nothing or were enti-
tled to generalizable knowledge gained through the
study (see Table 4). One respondent cited a “vague no-
tion that the research is good for everybody” while an-
other explained that research “has to have some kind of
outcome that the larger society could draw on and
build… on.” Several respondents also stressed the need
for communicating study results as “an obligation to
make your findings public.”
Respondents were asked what benefits they believed
community members should receive, regardless of exist-
ing REB requirements or legislation. These responses fell
into three categories: no benefits; access to information
about the results (including broader societal impacts of
the information generated from the study such as new
technologies or polices); and access to the intervention
being researched (see Table 5). Well over half of respon-
dents cited access to information generated by the study
as a requirement for conducting ethical research, but
benefitting from the knowledge gained through research
clearly varied in definition between respondents. Some
felt this was limited to having access to the final study
results, while others believed that this knowledge should
be translated into improvements in the community, such
as policy changes or improvements in health and med-
ical treatments and procedures. One respondent voiced
that researchers don’t value communication with com-
munities and stakeholders as much a publication in
peer-reviewed publications.
A few respondents felt that community members
should also have access to the therapy or intervention
under investigation if it demonstrated a benefit to partic-
ipants. One respondent explained that as pharmaceutical
companies were profiting and benefiting from tax
breaks, “…therefore the obligation should be that they
are contributing to the health and well-being of the com-
munity…” Another respondent explained, “…ethically
there absolutely is an obligation on the sponsor in this
case to make efforts to ensure that the intervention is
available and to contribute to addressing problems that
might frustrate that intervention from being available.”
When asked for an ethical rationale as to why commu-
nity members should benefit from research, respondents
generally struggled to define a specific rationale. Some
respondents indicated that benefits and an ethical ra-
tionale were dependent on a specific definition of
community, such as within certain geographic boundar-
ies or defined by some common connection. Severalrespondents evaded the question, while again referring
to vague benefits, such as knowledge exchange. Interest-
ingly, several respondents cited an ethical obligation to
taxpayers as a rationale for providing benefits to com-
munity members: “…if Canadians are paying for re-
search…there should be benefits for Canadian
communities.”
Discussion
Our analysis of the interviews identified three challenges
when considering whether and what benefits are owed
to research participants and their communities. Many
REB members understood providing access to the inter-
vention as being the role of the state, not the role of the
researcher. Similarly, many of the views on benefits were
shaped by the fact that REB members were based in
Canada, and expected the state to fulfill certain health
obligations. The interviews also highlighted that more
consideration, awareness, and research is needed around
benefits for participants and communities.
Identifying roles
The Canadian REB members we spoke to identified re-
searchers and the state as having distinctly different roles
with respect to health research and healthcare provision.
Respondents generally referred to the role of researchers
as being solely focused on research – not with providing
healthcare. Several respondents indicated that research
participants should not receive any benefits, they later
went on to explain that it was extremely important that
participants, community members, and citizens all have
access to a beneficial intervention through the health-
care system. Those respondents who did not believe any
benefits were necessary were largely still concerned with
access to medicines, but did not feel that providing this
access was the responsibility of researchers. While some
respondents stressed the importance of access to medi-
cines, this was often expressed as being an issue unre-
lated to ethical research. Similarly, most felt it is not the
role of REBs to compel researchers to provide
healthcare.
There was a concern from some respondents that re-
searchers were not doing enough to provide benefits for
participants, or that researchers were not even consider-
ing benefits for participants and communities in ethics
applications. However, few respondents supported re-
quiring researchers to include specific considerations
around benefits in their ethics applications. This re-
sponse mirrors the belief that researchers and the state
have distinct roles with respect to providing access to
healthcare and that research participants be clearly ad-
vised that researchers do not have a therapeutic role
[10]. Several respondents expressed a desire for re-
searchers to be more aware and proactive in choosing to
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recommending legislation or requirements forcing re-
searchers to provide certain benefits. The rationale for
this was the fact that every study is different, and there
was a reluctance to mandate the same requirements for
all types of research.
Several respondents made statements that indicated
that researchers sponsored by pharmaceutical companies
were different than the “average” researcher and that dif-
ferent requirements might apply to them. There was a
general view that the “average” researcher is a
university-based academic, professor or otherwise, and
several respondents cited pharmaceutical companies as
being a different case entirely, facing correspondingly
different ethical requirements. Because these companies
were presumed to be making substantial financial gains
based on the results of the study, REB members may
have felt that their obligations to participants are stron-
ger and more stringent. This raises issues around
whether who is conducting or funding the research cre-
ates special requirements around who benefits and what
benefits they should receive, and also around whether or
not financial gain creates special requirements and obli-
gations around benefits. This also raises broader con-
cerns around addressing inequalities and power
imbalances in research, particularly in low-income set-
tings where participants may be more vulnerable.
Research Ethics Board Members' Context
The assumption that the role of the researcher is funda-
mentally different from that of the state in terms of ac-
cess to medicines and healthcare is likely rooted in the
fact that all of the researchers interviewed are based in
Canada, a country with a comprehensive national
healthcare system. Their context of a high-income coun-
try with a well-functioning health system likely shaped
their assumptions and focus. The assumption that the
state is responsible for – and will provide – access to
needed medical care frees researchers to focus on re-
search, and to trust that advances will be accessible to
the general population. It’s worth noting, however, that
even in the Canadian context, access to affordable phar-
maceuticals is not guaranteed. According to the most re-
cent estimate of the Canadian Institutes of Health
Information, governments paid only 41.6 % of pharma-
ceutical expenditures in Canada in 2013 [11].
With respect to individual participants, respondents
were more concerned with obtaining informed consent
and freedom from undue inducement than with ensur-
ing participants had access to the intervention being
studied. For community members, there was a general
sense of confusion around why community members
should benefit, possibly due to existing community ac-
cess to healthcare in Canada. The fact that “community”is a difficult concept to define and the definition was left
intentionally broad in the interviews likely also contrib-
uted to the confusion.
Limitations
Since some universities do not publish REB members’
names or their contact information on their websites,
the researchers did not contact REB members from all
medical schools in Canada. There was no publicly ac-
cessible information for schools in Quebec and Eastern
Canada, thus these REB members from these regions are
not represented in this study. As a result, experiences
that are distinctive of that region and particularly norms
in the predominantly French speaking regions of the
country are not well represented in this study.
Conclusion
Our discussions with REB members based in Canada
highlighted assumptions around access to healthcare
and the role of the researcher that may not translate to
other countries and communities. In the Canadian con-
text, investigators can focus on conducting research,
while trusting, perhaps naively, that the state will pro-
vide access to beneficial health innovations. This is sim-
ply not be the reality in many low and middle income
settings. The effect of local context on shaping the con-
cerns of Canadian REB members demonstrates the im-
portance of requiring ethical approval from the country
where the trial is being conducted as well as the country
conducting the investigations, as REBs in the host coun-
try will likely be more attuned to the research context in
their communities. Above all, our research highlights a
need for continued discussion and awareness around
these issues and the need for further investigation that
includes the perspectives of both communities funding
human subject research and those in which this research
takes place. In this sense, REB members in Canada
might be seen as ‘well-meaning amateurs’ [12] who
would benefit from additional education as to these eth-
ical issues while REBs would benefit from additional
professionalization.
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